openPR Logo
Press release

US Biosimilars Market Opportunity & Clinical Pipeline Analysis Report

05-07-2018 09:04 AM CET | Health & Medicine

Press release from: Kuick Resarch

US Biosimilars Market Opportunity & Clinical Pipeline Analysis

“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:

* US Biosimilars Market Introduction
* US Biosimilars Regulatory Scenario
* Unique Features of US Biosimilars Market
* Impact of Biosimilars in US Market
* Impact of Reimbursement Policies on US Biosimilars Market
* Zarxio: First Approved Biosimilar in US
* US Biosimilar Clinical Pipeline By Company, Indication & Phase
* US Biosimilar Clinical Pipeline: 104 Biosimilars
* Marketed Biosimilars: 1 Biosimilar

Download Report Sample Weblink:

https://www.kuickresearch.com/report-US-Biosimilars-Market-Opportunity-&-Clinical-Pipeline-Analysis.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. US Biosimilars Market Introduction



2. US Biosimilars Regulatory Scenario



3. Unique Features of US Biosimilars Market



4. Impact of Biosimilars in US Market



5. New Biosimilar Categories with High Commercialization Potential

5.1 High Cost-Effectiveness

5.2 Competition

5.3 Nature of Indication

5.4 Nature of Biosimilars

5.5 Cost-Effective Production

5.6 Readily Availability of Biosimilars



6. Impact of Reimbursement Policies on US Biosimilars Market



7. Biobetters: Middle Ground between Biosimilars & Biologics



8. US Biosimilars Market Overview

8.1 Current Market Scenario

8.2 US Biosimilar Clincal Pipeline Overview



9. Zarxio: First Approved Biosimilar in US



10. US Biosimilars Market Dynamics

10.1 Research & Development

10.2 Increasing Demand for Biosimilars

10.3 Increasing Numbers Off-Patent Biologics

10.4 Lesser Competition

10.5 Strong Clinical Pipeline

10.6 Large Number of Indications to be Introduced



11. US Biosimilars Commercialization Challenges



12. US Biosimilars Future Prospects



13. US Biosimilars Market Guidelines

13.1 Scientific Considerations in Demonstration Biosimilarity to a Reference Product

13.2 Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein

Product to a Reference Product

13.3 Nonproprietary Naming of Biological Products

13.4 Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a

Reference Product



14. US Biosimilar Clinical Pipeline By Company, Indication & Phase

14.1 Research

14.2 Preclinical

14.3 Phase-I

14.4 Phase-I/II

14.5 Phase-II

14.6 Phase-III

14.7 Preregistration

14.8 Registered



15. Suspended & Discontued Biosimialrs in Clinical Pipeline

15.1 No Development Reported

15.2 Discountinued

15.3 Preregistration Submission Withdrawal



16. Competitive Landscape

16.1 Amgen

16.2 Apotex

16.3 Boehringer Ingelheim

16.4 Celltrion

16.5 Coherus BioSciences

16.6 Eli Lilly

16.7 EPIRUS Biopharmaceuticals

16.8 Finox Biotech

16.9 Harvest Moon Pharmaceuticals

16.10 Hospira

16.11 Intas Biopharmaceuticals

16.12 Juno Therepeutics (Opus Bio)

16.13 Merck

16.14 Momenta Pharmaceuticals

16.15 Mylan

16.16 Nora Therapeutics

16.17 Novartis

16.18 Oncobiologics

16.19 Pfenex

16.20 Pfizer

16.21 Sandoz

16.22 Wockhardt

Figure 1-1: Benefits of Biosimilar Introduction in US

Figure 1-2: Present Limitations of Biosimilars in US

Figure 1-3: FDA’s Requirements for Biosimilar Products

Figure 2-1: Criterias for Similarity Formulated by Food and Drug Administration (FDA)

Figure 4-1: Global Sales of Neupogen/Neulasta (USD Million), 2012-2014

Figure 4-2: Global Sales of Epogen (USD Million), 2012-2014

Figure 4-3: Global Sales of Neulasta (USD Million), 2012-2014

Figure 4-4: Shares of Amgen Products Exposed to Biosimilars Competition (USD Million), 2014

Figure 5-1: Factors Responsible for Significant Revenue Generation

Figure 7-1: Properties of Biobetters

Figure 7-2: Few Advantages of Biobetters

Figure 7-3: Disadvantages of Biobetters

Figure 8-1: US- Estimated Humira Sales (USD Million), 2012-2014

Figure 8-2: Global Remicade Sales (USD Million), 2012-2014

Figure 8-3: US- MabThera/Rituxan Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014-Q3 2015

Figure 8-4: US-Herceptin Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014- Q3 2015

Figure 8-5: Global Herceptin Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014-Q3 2015

Figure 8-6: Estimated Global Aranesp Sales (USD Million), 2012-2014

Figure 8-7: US- Estimated Aranesp Sales (USD Million), 2012-2017

Figure 8-8: Estimated Sales of Selected Biologics Exposed to Biosimilars Competition, 2014 (USD Million)

Figure 8-9: Estimated Shares of Selected Biologics Exposed to Biosimilars Competition (USD Million), 2014

Figure 8-10: Rank of US among Different Diabetes Prone Countries

Figure 8-11: US Biosimilar Pipeline by Phase (%),2016

Figure 8-12: US Biosimilar Pipeline by Phase (Number),2016

Figure 8-13: No Development Reported US Biosimilar All Pipeline by Phase (%),2016

Figure 8-14: No Development Reported US Biosimilar All Pipeline by Phase (Number),2016

Figure 8-15: Discontinued US Biosimilar All Pipeline by Phase (%),2016

Figure 8-16: Discontinued US Biosimilar All Pipeline by Phase (Numbers),2016

Figure 16-1: Amgen Clinical Pipeline

Figure 16-2: Coherus Bioscience Clinical Pipeline

Figure 16-3: EPIRUS Biopharmaceuticals- Clinical Pipeline

Figure 16-4: Merck Clinical Pipeline

Figure 16-5: Novartis Clinical Pipeline

Figure 16-6: Oncobiologics-Clinical Pipeline

Figure 16-7: Pfenex Clinical Piepline

Figure 16-8: Sandoz Clinical Pipeline



List of Tables



Table 2-1: Major Regulatory Differences Related to Biosimilars in US & EU

Table 2-2: Differences between Biosimilars Applications & Biologics License Applications

Table 4-1: Comparison of Neupogen vs. Zarxio Cost

Table 4-2: Competition to Neupogen

Table 4-3: Amgen’s Biosimilar Competitors in US

Table 4-4: Categories with Potential to Generate Significant Revenues in US Market

Table 5-1: Biosimilars under Food and Drug Administration (FDA) Review

Table 6-1: Categories of Medicare Plan

Table 6-2: Estimated Reimbursement of Zarxio according to Medicare B

Table 7-1: Few Examples of Biologics, Biosimilars and Biobetters

Table 8-1: Biosimilars with High Commercialization Potential in US, 2013-2024

Table 8-2: Companies Involved in Marketing of Rituximab

Table 8-3: Categories with High Potential for Biosimilar Revenue Generation

Table 16-1: Celltrion Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Biosimilars Market Opportunity & Clinical Pipeline Analysis Report here

News-ID: 1040986 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Bio

Bio Pharma Buffer Market – A comprehensive study by Key Players: Bio-Rad, Lonz …
Latest Market intelligence report released by HTF MI with title "COVID-19 Outbreak-Global Bio Pharma Buffer Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020" is designed covering micro level of analysis by manufacturers and key business segments. The COVID-19 Outbreak-Global Bio Pharma Buffer Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary
IVIG Market Anticipated a Noteworthy CAGR during 2019-2024 & Companies Included …
A report added to the rich database of Qurate Business Intelligence, titled “World IVIG Market by Product Type, Players and Regions - Forecast to 2024”, provides a 360-degree overview of the Global market. Approximations associated with the market values over the forecast period are based on empirical research and data collected through both primary and secondary sources. The authentic processes followed to exhibit various aspects of the market makes the
Green & Bio-based Solvents Market Analysis, Demand, & Opportunities till 2023 | …
A latest research report titled as “Green & Bio-based Solvents Market for Paints & Coatings, Printing Inks, Commercial & Domestic Cleaning, Adhesives & Sealants, Pharmaceutical, Cosmetics, and Other Applications - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023” has been recently added to the vast portfolio of Market Research Reports Search Engine (MRRSE) online research offerings. This report is a professional and in-depth analysis on the
Global Bioplastics (Bio-plastics,Bio plastics) Market 2018 - Braskem, BASF
Apex Market Reports, recently published a detailed market research study focused on the “Bioplastics (Bio-plastics,Bio plastics) Market” across the global, regional and country level. The report provides 360° analysis of “Bioplastics (Bio-plastics,Bio plastics) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Bioplastics
Worldwide Bio-Electronics Market 2025 – Global Analysis and Forecasts by Type …
Bio-Electronics is defined as the electronic devices used for bio-medical purposes, and helps in creating and evaluating the new technologies for better understanding of biological systems. The increasing demand of bio-electronics to meet the overwhelming need in healthcare industry will boost the bio-electronics market in forecast period. Furthermore, the growth in research of implantable devices for developing robust and reliable implantable medical devices will increase the demand of bio-electronics in
Bio Electronics and Bio Sensors Market Forecasts, 2017-2025
Description: The global bio electronic market is valued USD $15 billion in 2016 and is expected to grow at a CAGR of 11.6% during the forecast period 2017-2025. The market is driven by various factors such as rapid advancement in semiconductor technology, high demand in implantable medical devices, increasing prevalence of neural and cardiac diseases among others. The emerging healthcare technologies such as lab on chip, ambulatory surgical centres, and personalized devices are